Data advantage of foreign stents

A cardiologist in Nagpur performs two similar angioplasties. But the stents inside his patients tell two very different stories. One gets Indian-made devices under a government scheme. The other insists on an imported brand.

This contrast is now common across India. Price caps pushed foreign stent makers into a corner in 2017. But they never left.

And now, they’re back with new valves, pacemakers, and high-margin cardiac devices. Domestic players, meanwhile, grew fast but still struggle with data, technology, and trust.

Tune in.

Daybreak is produced from the newsroom of The Ken, India’s first subscriber-only business news platform. Subscribe for more exclusive, deeply-reported, and analytical business stories.